论文部分内容阅读
目的了解骨显像评价89Sr对前列腺癌骨转移的治疗效果。方法通过骨显像确认骨转移的53例前列腺癌患者,静脉给药89Sr治疗,剂量1.48~2.22MBq(40~60μC)/kg,3~6个月后复查骨显像,与治疗前对比。结果(1)治疗后39(73.6%)例骨转移灶数目较治疗前明显减少或消失,10(18.9%)例稳定,4(7.5%)例恶化;(2)骨转移灶代谢活性即ROI比值(T/NT),由治疗前的(4.8±3.3)下降到(3.2±2.7);(3)部分病例可发现新生转移灶,范围扩大,核素浓集程度加深,临床改善和预后不佳。结论骨显像评价89Sr治疗前列腺癌骨转移,客观、全面,对预后评价也有较高的临床价值。
Objective To evaluate the therapeutic effect of 89Sr on bone metastasis of prostate cancer by bone imaging. Methods 53 cases of prostate cancer with bone metastasis confirmed by bone imaging were treated with 89Sr intravenously and the dose was 1.48-2.22MBq (40-60μC) / kg. Bone imaging was observed after 3-6 months and compared with those before treatment. Results (1) The number of bone metastases in 39 cases (73.6%) decreased or disappeared after treatment, 10 (18.9%) cases were stable and 4 (7.5%) cases were deteriorated. (2) The metabolic activity of bone metastases was ROI (T / NT) decreased from (4.8 ± 3.3) before treatment to (3.2 ± 2.7); (3) Neogenetic metastases were found in some cases, the range was expanded, the concentration of radionuclide was deepened, and clinical improvement and prognosis good. Conclusion Bone imaging evaluation 89Sr treatment of prostate cancer bone metastasis, objective, comprehensive, prognostic evaluation also has high clinical value.